Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc. (GRCL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
grcl · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Gracell Biotechnologies Inc. (GRCL) measures how much investors pay for each dollar of the company's trailing earnings. GRCL's current PE ratio of N/A is calculated by dividing its stock price of $10.25 by its TTM earnings per share of -$44.87.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2018 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Gracell Biotechnologies Inc.You GRCL | $198M | N/A | — | -$44.87 |
 Albireo Pharma, Inc. ALBO | $916M | N/A | — | -$7.87 |
 Crescent Biopharma, Inc. CBIO | $476M | N/A | — | -$14.78 |
 Chimerix, Inc. CMRX | $801M | N/A | — | -$0.99 |
 EQRx, Inc. EQRX | $1.1B | 5.68x | — | $0.43 |
 Ethzilla Corp. ETHZ | $56M | N/A | — | -$5517.71 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-44.87 | — | |
2021-12-31 FY2021 | — | $-35.42 | — | |
2020-12-31 FY2020 | — | $-15.04 | — | |
2019-12-31 FY2019 | — | $-33.36 | — | |
2018-12-31 FY2018 | — | $-15.34 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Gracell Biotechnologies Inc. (GRCL) measures how much investors pay for each dollar of the company's trailing earnings. GRCL's current PE ratio of N/A is calculated by dividing its stock price of $10.25 by its TTM earnings per share of -$44.87.
Frequently asked questions
GRCL pe ratio · 6 questionsGRCL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $10.25 and TTM EPS of -$44.87. Data sourced from Financial Modeling Prep via GRCL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gracell Biotechnologies Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09